Weave Bio is an AI-native, cloud-based life sciences platform that automates regulatory workflows for drug development. Its flagship module, AutoIND, streamlines preparation of Investigational New Drug (IND) applications by automatically drafting sections from a company's own data, public information, and current regulatory guidelines. The platform serves pharmaceutical companies, biotech firms, CROs, and regulatory consultants across data extraction, authoring, review, publishing, and health-authority responses. Founded in 2022 by Ari Caroline, Shlomo Klapper, and Umut Eser, Weave won the 2024 BioTech AI Innovation of the Year award and partnered with Parexel in 2025. It has raised roughly $36M, including a $20M Series A.
Weave is publicly traded
IPO'd on November 11, 2021
This company is no longer available on our private secondary market. Shares can be traded publicly under WEAV.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2022
Employees
11–50
Total Funding
$265.12M
7 rounds
Last Private Valuation
$1.5B
November 11, 2021
Total raised $265.12M across 7 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
IPO (NYSE: WEAV)
Date
November 11, 2021
Amount
$120M
Valuation
$1.5B
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| November 11, 2021 | IPO (NYSE: WEAV) | $120M | $1.5B | Morgan Stanley, J.P. Morgan, Bank of America |
| October 24, 2019 | Series D | $70M | $0.97B | Tiger Global Management |
| December 2018 | Series C | $37.5M | — | Lead Edge Capital |
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Valuation indexed to 1.0× at the selected entry round. Valuation marks are estimates and may contain errors. Hover each dot to compare.
Entry · Series D
$1.0B
Oct 2019
Weave today
$1.5B
Nov 2021 · latest mark
Weave multiple
1.5x
valuation uplift since first round
Y-axis is logarithmic. Hollow dots = estimated valuations. Does not represent realized investor returns.
Yes, Weave is publicly traded under the ticker symbol WEAV on the NYSE. The company went public in November 11, 2021.
Weave trades under the ticker symbol WEAV on the NYSE. It began trading in November 11, 2021.
Weave (WEAV on the NYSE) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker WEAV to place an order.
Weave went public in November 11, 2021 via ipo, with an offering valuation of approximately $1.5B. Weave Communications completed its initial public offering on November 11, 2021, trading on the NYSE under ticker WEAV. The IPO priced 5 million shares at $24 per share, raising $120 million. Current stock price as of May 2026 is approximately $4.91 with a market cap of $397.25M.
Weave raised $265.12M across 7 disclosed funding rounds prior to its public listing.
Weave was co-founded by Ari Caroline, Shlomo Klapper, and Umut Eser in 2022.
Weave is headquartered in New Haven, Connecticut, United States.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.